Modified recombinant human erythropoietin with potentially reduced immunogenicity. Susantad T, Fuangthong M, Tharakaraman K, Tit-Oon P, Ruchirawat M, Sasisekharan R. Sci Rep. 2021 Jan 15;11(1):1491.

15 Jan 2021
0

Modified recombinant human erythropoietin with potentially reduced immunogenicity.

Susantad T, Fuangthong M, Tharakaraman K, Tit-Oon P, Ruchirawat M, Sasisekharan R.

Sci Rep. 2021 Jan 15;11(1):1491.

Tags

Share this

Related Posts

Ruengsangtongkul, S.; Chaisan, N.; Thongsornkleeb, C.; Tummatorn, J.; Ruchirawat, S. Rate Enhancement in CAN-Promoted Pd(PPh3)2Cl2-Catalyzed Oxidative Cyclization: Synthesis of 2-Ketofuran-4-carboxylate Esters. Org. Lett. 2019, 21, 2514–2517.

Recent Posts

Efficacy of Andrographis paniculata extract treatment in mild to moderate COVID-19 patients being treated with favipiravir: A double-blind, randomized, placebo-controlled study (APFaVi trial)